scholarly journals Decreased Cure and Increased Recurrence Rates for Clostridium difficile Infection Caused by the Epidemic C. difficile BI Strain

2012 ◽  
Vol 55 (3) ◽  
pp. 351-357 ◽  
Author(s):  
Laurica A. Petrella ◽  
Susan P. Sambol ◽  
Adam Cheknis ◽  
Kristin Nagaro ◽  
Yin Kean ◽  
...  
Keyword(s):  
Clostridium Difficile ◽  
Clostridium Difficile Infection ◽  
Recurrence Rates

scholarly journals Zinc Level and Its Role in Recurrent Clostridium difficile Infection: A Case Report and Literature Review

2020 ◽  
Vol 8 ◽  
pp. 232470962094131
Author(s):  
Swetha Parvataneni ◽  
Avinash R. Dasari
Keyword(s):  
United States ◽  
Case Report ◽  
Clostridium Difficile ◽  
Clostridium Difficile Infection ◽  
Zinc Supplementation ◽  
The United States ◽  
Zinc Level ◽  
Recurrence Rates ◽  
Oral Transmission ◽  
Recurrent Clostridium Difficile Infection

Clostridium difficile infection is a common nosocomial infection in US hospitals, accounting for approximately 12 800 deaths annually in the United States. These infections are often associated with the use of antibiotics, which can alter the gut microbiome and thus render patients susceptible to C difficile infection. C difficile is often spread via fecal oral transmission. Multiple medications have been developed, but recurrence rates reach 60% after treatment. Recent data have shown that zinc supplementation decreases the recurrence of C difficile infection. In this article, we present a case of recurrent C difficile infection with zinc deficiency in which zinc supplementation improved the symptoms and reduced the incidence of recurrence.

Safety and Efficacy of Fidaxomicin in Patients with Clostridium Difficile Infection

2013 ◽  
Vol 5 ◽  
pp. CMT.S7279
Author(s):  
Monica A. Donnelley ◽  
Jeremiah J. Duby ◽  
Christine S. Cocanour
Keyword(s):  
Clostridium Difficile ◽  
Clostridium Difficile Infection ◽  
Systemic Absorption ◽  
Oral Vancomycin ◽  
Recurrence Rates ◽  
Virulent Strains ◽  
United States Food ◽  
The Cost ◽  
Healthcare Epidemiology ◽  
Systemic Infections

Fidaxomicin is a bactericidal macrolide that is indicated for the treatment of Clostridium difficile infection (CDI) in adults. Fidaxomicin is not effective for the treatment of systemic infections due to minimal systemic absorption. Until recently, oral vancomycin was the only medication with United States Food and Drug Administration (FDA) approval for the treatment of CDI. In clinical studies, fidaxomicin demonstrated noninferiority to vancomycin for the treatment of CDI. Lower recurrence rates of CDI with fidaxomicin than with oral vancomycin were observed. The lower recurrence rates were not observed with highly virulent strains of C. difficile. Lower recurrence rates of CDI with fidaxomicin are believed to be associated with its narrow spectrum of activity. Fidaxomicin was approved for use after publication of the most recent guideline from the Society for Healthcare Epidemiology of America (SHEA) and Infectious Diseases Society of America (IDSA). However, its current place in clinical practice is unknown. The cost of fidaxomicin should be considered when prescribing this medication.

scholarly journals A Retrospective Study of Recurrence Rates of Clostridium difficile Infection After the Use of Fidaxomicin in a Single Institution

2016 ◽  
Vol 3 (suppl_1) ◽  
Author(s):  
Robert Chow ◽  
Melinda Monteforte ◽  
Eric Spitzer ◽  
Lorenzo F. Ottaviano ◽  
Amanda Phoenix ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Clostridium Difficile ◽  
Clostridium Difficile Infection ◽  
Single Institution ◽  
Recurrence Rates

Self-Administered Home Series Fecal “Minitransplants” for Recurrent Clostridium difficile Infection on a Rectal Remnant

2015 ◽  
Vol 24 (4) ◽  
pp. 531-533 ◽  
Author(s):  
Daniel Popa ◽  
Mihaela Laszlo ◽  
Lidia Ciobanu ◽  
Elena Ucenic ◽  
Manuela Mihalache ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Clostridium Difficile ◽  
Clostridium Difficile Infection ◽  
Toxic Megacolon ◽  
Fecal Microbiota ◽  
Recurrent Infections ◽  
Resonance Imaging ◽  
Vaginal Infection ◽  
Fecal Microbiota Transplant ◽  
Recurrent Clostridium Difficile Infection

A fecal microbiota transplant has proved to be an extremely effective method for patients with recurrent infections with Clostridium difficile. We present the case of a 65-year-old female patient with multiple Clostridium difficile infection (CDI) relapses on the rectal remnant, post-colectomy for a CDI-related toxic megacolon. The patient also evidenced associated symptomatic Clostridium difficile vaginal infection. She was successfully treated with serial fecal “minitransplants” (self-administered at home) and metronidazole ovules.Abbreviations: GI: gastrointestinal; MRI: magnetic resonance imaging; CDI: Clostridium difficile infection; FMT: fecal microbiota transplant.

Serendipity in Refractory Celiac Disease: Full Recovery of Duodenal Villi and Clinical Symptoms after Fecal Microbiota Transfer

2016 ◽  
Vol 25 (3) ◽  
pp. 385-388 ◽  
Author(s):  
Yvette H. Van Beurden ◽  
Tom Van Gils ◽  
Nienke A. Van Gils ◽  
Zain Kassam ◽  
Chris J.J. Mulder ◽  
...  
Keyword(s):  
Celiac Disease ◽  
T Cell ◽  
Clostridium Difficile ◽  
Clostridium Difficile Infection ◽  
Cell Lymphoma ◽  
Fecal Microbiota ◽  
Disease Type ◽  
T Cell Lymphoma ◽  
Type Ii ◽  
Refractory Celiac Disease

Treatment of refractory celiac disease type II (RCD II) and preventing the development of an enteropathy associated T-cell lymphoma in these patients is still difficult. In this case report, we describe a patient with RCD II who received fecal microbiota transfer as treatment for a recurrent Clostridium difficile infection, and remarkably showed a full recovery of duodenal villi and disappearance of celiac symptoms. This case suggests that altering the gut microbiota may hold promise in improving the clinical and histological consequences of celiac disease and/or RCD II. Abbreviations: CDI: Clostridium difficile infection; EATL : enteropathy associated T-cell lymphoma; FMT: fecal microbiota transfer; IEL: intraepithelial lymphocytes; RCD II: refractory celiac disease type II; TPN: total parenteral nutrition.

Sign in / Sign up

Export Citation Format

Share Document